Your browser is no longer supported. Please, upgrade your browser.
Outlook Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.36 Insider Own1.10% Shs Outstand170.12M Perf Week7.69%
Market Cap326.77M Forward P/E- EPS next Y-0.16 Insider Trans- Shs Float123.14M Perf Month1.45%
Income-53.20M PEG- EPS next Q-0.06 Inst Own10.70% Short Float3.51% Perf Quarter-36.07%
Sales- P/S- EPS this Y48.30% Inst Trans0.09% Short Ratio2.79 Perf Half Y-37.22%
Book/sh0.03 P/B46.67 EPS next Y66.70% ROA-187.70% Target Price7.08 Perf Year2.94%
Cash/sh0.06 P/C22.54 EPS next 5Y- ROE-772.40% 52W Range0.93 - 4.26 Perf YTD2.94%
Dividend- P/FCF- EPS past 5Y58.80% ROI- 52W High-67.14% Beta0.86
Dividend %- Quick Ratio3.20 Sales past 5Y- Gross Margin- 52W Low50.78% ATR0.09
Employees9 Current Ratio3.20 Sales Q/Q- Oper. Margin- RSI (14)53.00 Volatility8.33% 6.95%
OptionableNo Debt/Eq2.57 EPS Q/Q3.10% Profit Margin- Rel Volume1.24 Prev Close1.39
ShortableYes LT Debt/Eq2.37 Earnings- Payout- Avg Volume1.55M Price1.40
Recom2.00 SMA205.90% SMA50-3.14% SMA200-33.47% Volume1,910,237 Change0.72%
Sep-11-19Initiated Ladenburg Thalmann Buy $9
May-16-19Initiated Oppenheimer Outperform $12
Apr-22-19Initiated Ascendiant Capital Markets Buy
Jan-25-22 08:05AM  
Jan-19-22 08:05AM  
Jan-12-22 10:35AM  
Jan-04-22 08:35AM  
Dec-22-21 08:05AM  
Dec-15-21 08:05AM  
Dec-09-21 08:05AM  
Nov-29-21 04:15PM  
Nov-24-21 06:49AM  
Nov-23-21 10:30PM  
Nov-13-21 11:00AM  
Nov-10-21 08:05AM  
Nov-04-21 02:30PM  
Nov-03-21 08:05AM  
Oct-15-21 08:41AM  
Oct-12-21 12:00PM  
Oct-07-21 08:05AM  
Oct-05-21 08:05AM  
Sep-28-21 08:05AM  
Sep-21-21 08:05AM  
Sep-13-21 08:05AM  
Sep-08-21 08:05AM  
Aug-26-21 09:57AM  
Aug-13-21 08:05AM  
Aug-11-21 08:05AM  
Aug-03-21 05:34PM  
Jul-07-21 08:05AM  
Jul-02-21 05:04AM  
Jun-14-21 08:05AM  
Jun-08-21 08:05AM  
May-27-21 08:05AM  
May-18-21 06:15AM  
May-14-21 08:05AM  
May-12-21 08:05AM  
Mar-31-21 09:23AM  
Mar-23-21 04:49AM  
Mar-04-21 09:00AM  
Feb-17-21 08:05AM  
Feb-16-21 08:05AM  
Feb-11-21 08:05AM  
Feb-04-21 11:18AM  
Feb-02-21 04:05PM  
Jan-28-21 11:59PM  
Jan-12-21 08:05AM  
Jan-05-21 08:00AM  
Dec-23-20 09:05AM  
Dec-07-20 08:04PM  
Dec-01-20 08:05AM  
Nov-19-20 08:05AM  
Nov-11-20 09:05AM  
Nov-05-20 08:05AM  
Nov-03-20 08:35AM  
Oct-22-20 08:00AM  
Oct-13-20 08:05AM  
Oct-12-20 03:30PM  
Oct-07-20 08:05AM  
Sep-30-20 08:05AM  
Sep-08-20 08:05AM  
Aug-26-20 02:52PM  
Aug-14-20 08:05AM  
Jul-17-20 08:05AM  
Jul-07-20 08:05AM  
Jun-25-20 09:43AM  
Jun-23-20 08:00AM  
Jun-17-20 08:05AM  
Jun-11-20 08:05AM  
Jun-10-20 08:12PM  
Jun-09-20 08:05AM  
Jun-03-20 08:05AM  
May-26-20 08:05AM  
May-20-20 08:39AM  
May-15-20 08:00AM  
Apr-21-20 08:05AM  
Apr-16-20 09:16AM  
Apr-15-20 08:35AM  
Apr-14-20 08:05AM  
Mar-19-20 09:32AM  
Mar-05-20 08:00AM  
Feb-26-20 02:26PM  
Feb-25-20 09:15AM  
Feb-24-20 08:00AM  
Feb-18-20 01:28PM  
Feb-14-20 08:00AM  
Feb-04-20 08:00AM  
Jan-28-20 08:00AM  
Dec-26-19 08:00AM  
Dec-24-19 07:24AM  
Dec-23-19 09:00AM  
Dec-19-19 08:00AM  
Dec-03-19 08:00AM  
Nov-13-19 10:44AM  
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TRENARY C RUSSELL IIICEO and PresidentDec 06Buy1.3925,00034,75035,000Dec 06 05:27 PM
Dagnon TerryChief Operating OfficerDec 06Buy1.3825,20134,7771,163,058Dec 06 05:26 PM
Dagnon TerryChief Operating OfficerDec 03Buy1.4210,00014,2001,137,857Dec 03 04:32 PM
Evanson JeffChief Commercial OfficerDec 03Buy1.3435,20047,1681,177,130Dec 06 05:25 PM
Sukhtian Faisal GhiathDirectorDec 02Buy1.4018,00025,20038,000Dec 02 05:08 PM
Haddadin Yezan MuntherDirectorDec 02Buy1.3910,00013,90030,000Dec 02 05:09 PM
TRENARY C RUSSELL IIICEO and PresidentDec 02Buy1.4010,00014,00010,000Dec 02 05:07 PM
Sukhtian Ghiath M.DirectorNov 29Buy1.2516,000,00020,000,00027,834,257Dec 01 07:32 PM
KENYON LAWRENCE ACEO, Pres, CFO, Treas & SecyApr 20Buy1.8310,00018,30018,926Apr 20 07:54 PM
Haddadin Yezan MuntherDirectorApr 19Buy1.8210,00018,20020,000Apr 20 07:56 PM
Sukhtian Faisal GhiathDirectorApr 19Buy1.8210,00018,20020,000Apr 20 07:55 PM
Evanson JeffChief Commercial OfficerFeb 23Sale2.098,55417,8611,141,930Feb 25 08:52 PM
Dagnon TerryChief Operating OfficerFeb 23Sale2.0915,90033,1991,127,857Feb 25 08:51 PM
Evanson JeffChief Commercial OfficerFeb 12Sale2.5556,973145,2811,150,484Feb 17 09:14 PM
Dagnon TerryChief Operating OfficerFeb 12Sale2.5563,700162,4351,143,757Feb 17 09:13 PM
Syntone Ventures LLC10% OwnerFeb 03Buy1.003,000,0003,000,00019,823,045Feb 04 08:54 PM
Sukhtian Ghiath M.DirectorFeb 02Buy1.008,360,0008,360,00010,820,630Feb 02 05:32 PM